GMT logo

Genomtec S.A. Stock Price

WSE:GMT Community·zł56.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

GMT Share Price Performance

zł3.77
-3.91 (-50.91%)
zł3.77
-3.91 (-50.91%)
Price zł3.77

GMT Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slight risk with mediocre balance sheet.

4 Risks
0 Rewards

Genomtec S.A. Key Details

zł15.0k

Revenue

zł8.1m

Cost of Revenue

-zł8.1m

Gross Profit

zł2.9m

Other Expenses

-zł11.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.73
-54,113.33%
-73,393.33%
4.2%
View Full Analysis

About GMT

Founded
2008
Employees
26
CEO
Miron Tokarski
WebsiteView website
www.genomtec.com

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was incorporated in 2008 and is based in Wroclaw, Poland.

Recent GMT News & Updates

Recent updates

No updates